Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Health System Impact Fellowships - PostDoc Western Canada 2-year

University of British Columbia

$54,250.00

Implementation of a clinical population screening program for BRCA1/2 mutations among individuals of Ashkenazi Jewish ancestry

FY 2022-23

Summary
Approximately 1 in 40 individuals who have Ashkenazi Jewish ancestry are born with a mutation in the BRCA1 or BRCA2 gene, in comparison to 1 in 300 in the general population. These individuals are at a high risk to develop multiple cancers over their lifetime, including breast and ovarian cancer for females. Genetic testing can help to determine whether an individual has a BRCA1/2 mutation. Once identified to have a mutation, patients can become eligible for more cancer screening (e.g. yearly breast mammograms and MRIs for females) and have the option to undergo surgery to reduce their risk (e.g. removal of ovaries). These can reduce the risk of cancer or help to detect it early. Current programs to identify individuals with BRCA1/2 mutations are not effective; less than 50% of these individuals are identified. To address this gap in cancer care, the Hereditary Cancer program at BC Cancer has designed a population screening program, which will allow anyone of Ashkenazi Jewish ancestry to obtain testing for BRCA1/2 gene mutations. A population screening program comes with many challenges, including lack of public awareness of BRCA1/2 mutations as well as limited genetic professionals (genetic counsellors) who can provide patients with education and support as they undergo testing. To help address these challenges, the proposed project will involve designing and implementing a public education campaign, that will help to improve awareness of the screening program and uptake of testing. The project will also include the adaptation of patient-facing digital tool that will help to educate and guide patients through the population screening program. This will help to reduce workload on the clinical team, provide support for patients and improve sustainability of the program.
Program
Health System Impact Fellowships - PostDoc Western Canada 2-year
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
484636
Name
Shickh Salma A
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Partnername
Michael Smith Health Research BC
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Fellowship : Health System Impact Fellowship Post Doctoral Fellows
Projecttitle
Implementation of a clinical population screening program for BRCA1/2 mutations among individuals of Ashkenazi Jewish ancestry
Programtype2
Fellowship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$54,250
Cihrequipment2
$0
Programname2
Health System Impact Fellowships - PostDoc Western Canada 2-year
Keyworddelim
Cancer Prevention; Genetic Diseases; Health Policy; Health Systems; Hereditary Cancer Syndromes; Knowledge Translation; Learning Health System; Population Screening; Public Health
Abstract
Approximately 1 in 40 individuals who have Ashkenazi Jewish ancestry are born with a mutation in the BRCA1 or BRCA2 gene, in comparison to 1 in 300 in the general population. These individuals are at a high risk to develop multiple cancers over their lifetime, including breast and ovarian cancer for females. Genetic testing can help to determine whether an individual has a BRCA1/2 mutation. Once identified to have a mutation, patients can become eligible for more cancer screening (e.g. yearly breast mammograms and MRIs for females) and have the option to undergo surgery to reduce their risk (e.g. removal of ovaries). These can reduce the risk of cancer or help to detect it early. Current programs to identify individuals with BRCA1/2 mutations are not effective; less than 50% of these individuals are identified. To address this gap in cancer care, the Hereditary Cancer program at BC Cancer has designed a population screening program, which will allow anyone of Ashkenazi Jewish ancestry to obtain testing for BRCA1/2 gene mutations. A population screening program comes with many challenges, including lack of public awareness of BRCA1/2 mutations as well as limited genetic professionals (genetic counsellors) who can provide patients with education and support as they undergo testing. To help address these challenges, the proposed project will involve designing and implementing a public education campaign, that will help to improve awareness of the screening program and uptake of testing. The project will also include the adaptation of patient-facing digital tool that will help to educate and guide patients through the population screening program. This will help to reduce workload on the clinical team, provide support for patients and improve sustainability of the program.
Competitiondate
202303
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Shickh, Salma A
Approvedterm
2 ans 0 mois
Cihrcontribution2
IHDCYH~ $54,250~ $0~